ImmunityBio (NASDAQ:IBRX – Get Free Report) is one of 282 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare ImmunityBio to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability. Earnings & Valuation This table […]